These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 31423335)

  • 61. Long-Term Safety and Efficacy of Lubiprostone in Opioid-induced Constipation in Patients with Chronic Noncancer Pain.
    Spierings ELH; Rauck R; Brewer R; Marcuard S; Vallejo R
    Pain Pract; 2016 Nov; 16(8):985-993. PubMed ID: 26328775
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation.
    Evans BW; Clark WK; Moore DJ; Whorwell PJ
    Cochrane Database Syst Rev; 2007 Oct; (4):CD003960. PubMed ID: 17943807
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effects of Kivia powder on gut health in patients with occasional constipation: a randomized, double-blind, placebo-controlled study.
    Udani JK; Bloom DW
    Nutr J; 2013 Jun; 12():78. PubMed ID: 23758673
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Safety and efficacy of the sodium-glucose cotransporter 1 inhibitor mizagliflozin for functional constipation: a randomised, placebo-controlled, double-blind phase 2 trial.
    Fukudo S; Endo Y; Hongo M; Nakajima A; Abe T; Kobayashi H; Nakata T; Nakajima T; Sameshima K; Kaku K;
    Lancet Gastroenterol Hepatol; 2018 Sep; 3(9):603-613. PubMed ID: 30056028
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Naloxegol for opioid-induced constipation in patients with noncancer pain.
    Chey WD; Webster L; Sostek M; Lappalainen J; Barker PN; Tack J
    N Engl J Med; 2014 Jun; 370(25):2387-96. PubMed ID: 24896818
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Colchicine for acute gout.
    van Echteld I; Wechalekar MD; Schlesinger N; Buchbinder R; Aletaha D
    Cochrane Database Syst Rev; 2014 Aug; (8):CD006190. PubMed ID: 25123076
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
    Highland KB; Distler O; Kuwana M; Allanore Y; Assassi S; Azuma A; Bourdin A; Denton CP; Distler JHW; Hoffmann-Vold AM; Khanna D; Mayes MD; Raghu G; Vonk MC; Gahlemann M; Clerisme-Beaty E; Girard M; Stowasser S; Zoz D; Maher TM;
    Lancet Respir Med; 2021 Jan; 9(1):96-106. PubMed ID: 33412120
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Systematic review with meta-analysis: lubiprostone efficacy on the treatment of patients with constipation.
    Passos MDCF; Takemoto MLS; Corradino GC; Guedes LS
    Arq Gastroenterol; 2020; 57(4):498-506. PubMed ID: 33331483
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Naldemedine (Symproic) for the Treatment Of Opioid-Induced Constipation.
    Hu K; Bridgeman MB
    P T; 2018 Oct; 43(10):601-627. PubMed ID: 30271103
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Correcting Naldemedine (Symproic) Product Summary.
    Cataldo M
    P T; 2017 Nov; 42(11):683. PubMed ID: 29089723
    [No Abstract]   [Full Text] [Related]  

  • 71. Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy: A Subgroup Analysis of Patients ≥ 65 Years of Age.
    Wild J; Webster L; Yamada T; Hale M
    Drugs Aging; 2020 Apr; 37(4):271-279. PubMed ID: 32086791
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Prevention and management of diarrhea associated with naldemedine among patients receiving opioids: a retrospective cohort study.
    Takagi Y; Osawa G; Kato Y; Ikezawa E; Kobayashi C; Aruga E
    BMC Gastroenterol; 2020 Jan; 20(1):25. PubMed ID: 32005157
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pharmacological Profile of Naldemedine, a Peripherally Acting
    Kanemasa T; Koike K; Takase K; Arai T; Nakamura A; Morioka Y; Hasegawa M
    J Pharmacol Exp Ther; 2020 Jun; 373(3):438-444. PubMed ID: 32169839
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A Renal Impairment Subgroup Analysis of the Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy.
    Webster LR; Hale ME; Yamada T; Wild JE
    J Pain Res; 2020; 13():605-612. PubMed ID: 32280263
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer.
    Katakami N; Harada T; Murata T; Shinozaki K; Tsutsumi M; Yokota T; Arai M; Tada Y; Narabayashi M; Boku N
    Ann Oncol; 2018 Jun; 29(6):1461-1467. PubMed ID: 32151367
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Opioid therapy duration before naldemedine treatment is a significant independent risk of diarrhea: a retrospective cohort study.
    Okamoto A; Ikemura K; Mizutani E; Iwamoto T; Okuda M
    J Pharm Health Care Sci; 2021 Feb; 7(1):3. PubMed ID: 33517900
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A Systematic Review of Naldemedine and Naloxegol for the Treatment of Opioid-Induced Constipation in Cancer Patients.
    Braun UK; Jackson LK; Garcia MA; Imam SN
    Pharmacy (Basel); 2024 Mar; 12(2):. PubMed ID: 38525728
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Influence of Brain Metastasis on Analgesia-Related Outcomes in Patients with Lung and Breast Cancers Treated with Naldemedine: A Propensity Score-Matched Analysis.
    Hanamoto A; Koseki T; Utsunomiya A; Ishihara T; Tobe T; Kondo M; Kijima Y; Matsuoka H; Mizuno T; Hayashi T; Yamada S
    J Clin Med; 2023 Nov; 12(22):. PubMed ID: 38002612
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Real-World Evidence for the Safety and Effectiveness of Naldemedine in the Management of Opioid-Induced Constipation in Patients With Cancer Pain: Post-hoc Subgroup Analysis of Post-marketing Surveillance in Japan.
    Naya N; Oka H; Hashimoto S; Morioka Y; Kizawa Y
    Cureus; 2023 Sep; 15(9):e46090. PubMed ID: 37900431
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.